Companies /Healthcare

Edwards Lifesciences Corp

NYSE: EW Medical Devices
$105.23
▼ $0.20 (−0.19%) today
Markets closed · 12:34am ET

24/7 Wall St. View

EW at a Glance

Valuation
Market cap
$60.6B
P/E ratio
61.3
Profitability
Revenue (TTM)
$6.7B
Profit margin
15.3%
EPS (TTM)
$1.72
Price
52-week range
$75 – $108
24/7 target
$129.66
Street target
$113.68
Earnings
Next report
Feb 8, 2027

Headquartered in Irvine, CA Fiscal year ends December NYSE: EW edwards.com

About Edwards Lifesciences

Edwards Lifesciences is a medical device company focused exclusively on structural heart disease. It reports sales across three product groups.

- **Transcatheter Aortic Valve Replacement (TAVR):** the SAPIEN platform, including SAPIEN 3 Ultra RESILIA. This is its largest business.
- **Transcatheter Mitral and Tricuspid Therapies (TMTT):** the PASCAL transcatheter edge-to-edge repair system (including PASCAL Ace with Capture Clarity and PASCAL Precision), the EVOQUE tricuspid valve replacement system, and the SAPIEN M3 transcatheter mitral valve replacement system. TMTT sales also include revenue related to Implantable Heart Failure Management.
- **Surgical:** surgical heart valves built on RESILIA tissue, the AUTUS pediatric pulmonary valve, and the ECLIPTIS surgical left atrial appendage system.

Edwards sells to hospitals in the United States, Europe, Japan and the rest of the world, with the U.S. representing the majority of sales. Its strategy centers on clinical evidence generation through trials such as PROGRESS, EARLY TAVR, CLASP IITR, TRISCEND II and ENCIRCLE, which aim to expand indications and reimbursement access. The company sold its Critical Care business in 2025 and now operates as a pure-play structural heart company. Updated

Latest Activity

52-week highs
43stocks hit new 52-week highs this week
  • MSIMotorola Solutions$530.42+7.7%
  • IBNICICI Bank$34.51+7.2%
  • EWEdwards Lifesciences$107.19+6.4%
  • TEVATeva$44.54+5.8%
  • FASTFastenal Company$55.55+4.4%
  • CAHCardinal Health$281.14+4.4%
  • MRNAModerna$223.37+4.1%
  • HUMHumana$450.47+3.9%
  • ICEIntercontinental Exchange$178.49+3.3%
  • KOCoca-Cola Company$99.26+3.3%

43 stocks notched fresh 52-week highs this week, with leadership spread across Motorola Solutions, ICICI Bank, Edwards Lifesciences, Coca-Cola, Humana and Fastenal. Motorola Solutions leads at $530.42, 7.7% past its prior peak.

EWEdwards Lifesciences
52-week high
$107.19
+1.30%vs prior 52-week high · Nov 12, 2026

A second straight record close for the valve maker at $107.19, 1.3% above Thursday's peak. Medtronic rose 1.88% and Abbott 1.22% the same day, so the medtech bid was broad.

Related stockstoday
  • MDTMedtronic plc.Competitor+1.9%
    Dec 31, 2025 · SEC 10-K
  • ABTAbbott LaboratoriesCompetitor+1.2%
    Dec 31, 2025 · SEC 10-K
  • BDXBecton DickinsonPartner+1.1%
    Sep 30, 2025 · SEC 10-K

Moves: Nov 13, 2026 · Alpha Vantage daily close

52-week highs
69stocks hit new 52-week highs this week
  • REGNRegeneron$904.35+14.2%
  • LNGCheniere Energy$279.8+9.9%
  • IBNICICI Bank$33.89+8.9%
  • EWEdwards Lifesciences$102.14+7.3%
  • AMCAMC Entertainment$3.14+7.1%
  • AJGArthur J. Gallagher &$281.61+6.6%
  • GWWGrainger$1,440.97+6.4%
  • BDXBecton Dickinson$211.86+6.4%
  • MMM3M Company$185.2+6.0%
  • BRK-ABerkshire Hathaway$857,486.43+5.8%

69 stocks printed fresh 52-week highs this week, with Regeneron clearing its prior peak by 14% at $904.35. Cheniere Energy, ICICI Bank, Grainger and Berkshire Hathaway also made the list.

EWEdwards Lifesciences
Q3 2026
EPS
$0.80
est $0.74+8.6%
Revenue
$1.72B
est $1.68B+2.3%

Mitral and tricuspid therapy sales jumped 44.3% year over year, enough for management to lift full-year sales growth guidance and adjusted EPS targets. The structural heart franchise is widening its lead on a crowding field.

Quarterly EPS — reported vs estimate
We delivered strong third-quarter growth of 11.2% which exceeded expectations, with broad-based performance across our businesses and regions, giving us the confidence to raise our full-year outlook.

A guidance raise from the structural heart leader lands while Abbott and Boston Scientific push harder into valve repair, and the growth came from every business and region. The $57 billion medtech name is defending share.

EW +0.96%since the quote
As I reflect on 2026 so far, I am proud of what our teams have accomplished and how we are positioning Edwards for strong, sustainable growth over the long term.

The CEO is steering investors toward the long game just as Boston Scientific pours $1.5 billion into the heart valve fight, and the $57 billion medtech leader has ticked up slightly since he said it. What matters next is whether third quarter structural heart growth backs up that confidence.

EW +0.96%since the quote
EWEdwards Lifesciences
New 52-week high$95.2+0.0% vs prior high · 2026-07-06

Edwards Lifesciences cleared its July 6 ceiling by a hair at $95.20, a fresh 52-week high for the $54.8 billion heart valve maker. The stock has climbed back from $78 in February without a new peak until now.

EWEdwards Lifesciences
Regular session
$88.67
-4.98%open $93.31

A 4.98% intraday drop to $88.67 is an outsized single-session move for a $51 billion medical-device name that rarely swings this hard. No confirmed catalyst yet, so watch whether the $93.31 open gets reclaimed.

EW Coverage

Frequently Asked Questions

What does Edwards Lifesciences do?

Edwards Lifesciences is a medical device company focused exclusively on structural heart disease. It reports sales across three product groups. - **Transcatheter Aortic Valve Replacement (TAVR):** the SAPIEN platform, including SAPIEN 3 Ultra RESILIA.

What is the EW stock price target?

24/7 Wall St.'s 12-month price target for EW is $129.66, rated Buy. The Wall Street consensus target is $113.68. EW price prediction →